Understanding the role of collagen biomarkers in diabetes is essential for identifying patients at high risk of chronic complications. A recent study highlights how specific extracellular matrix (ECM) proteins, such as PRO-C3 and PRO-C7, correlate with adverse clinical outcomes in type 1 diabetes (T1D). Furthermore, researchers identified these markers as independent predictors for kidney disease and cardiovascular mortality. Consequently, these findings offer a potential shift toward precision medicine in diabetic care.

Chronic kidney disease in diabetes often leads to impaired ECM remodeling and excessive collagen deposition. Specifically, this fibrotic process disrupts normal organ function and accelerates disease progression. In this observational cohort study, investigators measured serum levels of collagen type III (PRO-C3), type VII (PRO-C7), and type XXVIII (PRO-C28) formation. Additionally, they assessed collagen type III degradation (CTX-III) using ELISA techniques. The results demonstrated that elevated baseline levels of these proteins strongly correlate with a composite kidney endpoint and all-cause mortality.

Predicting Complications with Collagen Biomarkers in Diabetes

The study followed 662 participants over a median of 6.3 years. Notably, PRO-C3 and PRO-C7 emerged as significant risk markers. For every 1-SD increase in PRO-C3, the risk of kidney complications rose by 30%. Similarly, PRO-C7 was associated with a 24% increased risk for the same endpoint. Moreover, PRO-C7 served as a predictor for cardiovascular events, with an adjusted hazard ratio of 1.25. Therefore, monitoring these proteins could help clinicians identify high-risk individuals before significant organ damage occurs.

In contrast, markers of collagen degradation like CTX-III did not show the same predictive power for kidney or cardiovascular events. This suggests that the formation of new collagen fibers, rather than the breakdown of old ones, is the primary driver of diabetic fibrosis. Ultimately, integrating these biomarkers into clinical practice might allow for earlier intervention. However, further validation in diverse populations remains necessary to confirm these diagnostic thresholds.

Frequently Asked Questions

What is the clinical significance of PRO-C3 in type 1 diabetes?

PRO-C3 is a biomarker of collagen type III formation. In type 1 diabetes, elevated levels of PRO-C3 are independently associated with an increased risk of kidney complications and all-cause mortality, reflecting active fibrotic processes in the kidneys.

How do collagen biomarkers in diabetes assist in risk stratification?

These biomarkers provide a non-invasive way to measure extracellular matrix remodeling. By identifying high levels of proteins like PRO-C7, doctors can predict the likelihood of cardiovascular events and albuminuria progression more accurately than with traditional risk factors alone.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Rygg MO et al. Extracellular matrix proteins as risk markers for complications in type 1 diabetes. Diabet Med. 2026 Jun 20. doi: 10.1111/dme.70396. PMID: 42322163.

2. Genovese F et al. Markers of Collagen Formation and Degradation Reflect Renal Function and Predict Adverse Outcomes in Patients With Type 1 Diabetes. Diabetes Care. 2019;42(8):1482-1490. doi: 10.2337/dc18-2433.

3. Khan MS et al. Dysregulation of Extracellular Matrix in Diabetic Complications: Clinical Impacts and New Molecular Targets. Matrix Biology. 2026;112:45-62. doi: 10.1016/j.matbio.2026.05.003.